Yanming Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yanming Huang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Eric Verbeken
5 shared publicationsIvan De Scheerder
5 shared publicationsLan Wang
5 shared publications- Ivan De Scheerder
Department of Cardiology, University Hospitals Leuven, Leuven, Belgium
4 shared publications Shengqiao Li
4 shared publicationsXiaoshun Liu
4 shared publications
Latest Publications
- 1 June 2007
- Published by Taylor & Francis
- p. 325-337
Anti-migratory drugs and mechanisms of action
While all interventional cardiologists have access to pharmacopeial texts and databases and are aware of the growing number of pharmacological agents in the armamentarium, questions arise as to the ideal agent or combination of agents in differing patient situations. This superb text offers the reader coverage of all the major pharmacological therapies used in treating the cath lab patient from the practical, personal perspective of those actively involved in interventional cardiology. While all interventional cardiologists have access to pharmacopeial texts and databases and are aware of the growing number of pharmacological agents in the armamentarium, questions arise as to the ideal agent or combination of agents in differing patient situations. This superb text offers the reader coverage of all the major pharmacological therapies used in treating the cath lab patient from the practical, personal perspective of those actively involved in interventional cardiology. While all interventional cardiologists have access to pharmacopeial texts and databases and are aware of the growing number of pharmacological agents in the armamentarium, questions arise as to the ideal agent or combination of agents in differing patient situations. This superb text offers the reader coverage of all the major pharmacological therapies used in treating the cath lab patient from the practical, personal perspective of those actively involved in interventional cardiology. While all interventional cardiologists have access to pharmacopeial texts and databases and are aware of the growing number of pharmacological agents in the armamentarium, questions arise as to the ideal agent or combination of agents in differing patient situations. This superb text offers the reader coverage of all the major pharmacological therapies used in treating the cath lab patient from the practical, personal perspective of those actively involved in interventional cardiology. While all interventional cardiologists have access to pharmacopeial texts and databases and are aware of the growing number of pharmacological agents in the armamentarium, questions arise as to the ideal agent or combination of agents in differing patient situations. This superb text offers the reader coverage of all the major pharmacological therapies used in treating the cath lab patient from the practical, personal perspective of those actively involved in interventional cardiology. While all interventional cardiologists have access to pharmacopeial texts and databases and are aware of the growing number of pharmacological agents in the armamentarium, questions arise as to the ideal agent or combination of agents in differing patient situations. This superb text offers the reader coverage of all the major pharmacological therapies used in treating the cath lab patient from the practical, personal perspective of those actively involved in interventional cardiology.
- 1 June 2007
- Published by Taylor & Francis
- p. 325-337
Anti-migratory drugs and mechanisms of action
While all interventional cardiologists have access to pharmacopeial texts and databases and are aware of the growing number of pharmacological agents in the armamentarium, questions arise as to the ideal agent or combination of agents in differing patient situations. This superb text offers the reader coverage of all the major pharmacological therapies used in treating the cath lab patient from the practical, personal perspective of those actively involved in interventional cardiology. While all interventional cardiologists have access to pharmacopeial texts and databases and are aware of the growing number of pharmacological agents in the armamentarium, questions arise as to the ideal agent or combination of agents in differing patient situations. This superb text offers the reader coverage of all the major pharmacological therapies used in treating the cath lab patient from the practical, personal perspective of those actively involved in interventional cardiology. While all interventional cardiologists have access to pharmacopeial texts and databases and are aware of the growing number of pharmacological agents in the armamentarium, questions arise as to the ideal agent or combination of agents in differing patient situations. This superb text offers the reader coverage of all the major pharmacological therapies used in treating the cath lab patient from the practical, personal perspective of those actively involved in interventional cardiology. While all interventional cardiologists have access to pharmacopeial texts and databases and are aware of the growing number of pharmacological agents in the armamentarium, questions arise as to the ideal agent or combination of agents in differing patient situations. This superb text offers the reader coverage of all the major pharmacological therapies used in treating the cath lab patient from the practical, personal perspective of those actively involved in interventional cardiology. While all interventional cardiologists have access to pharmacopeial texts and databases and are aware of the growing number of pharmacological agents in the armamentarium, questions arise as to the ideal agent or combination of agents in differing patient situations. This superb text offers the reader coverage of all the major pharmacological therapies used in treating the cath lab patient from the practical, personal perspective of those actively involved in interventional cardiology. While all interventional cardiologists have access to pharmacopeial texts and databases and are aware of the growing number of pharmacological agents in the armamentarium, questions arise as to the ideal agent or combination of agents in differing patient situations. This superb text offers the reader coverage of all the major pharmacological therapies used in treating the cath lab patient from the practical, personal perspective of those actively involved in interventional cardiology.
- 1 January 2006
- Published by Taylor & Francis in Acute Cardiac Care
- Vol. 8 (4) , 210-216
Stent?based tempamine delivery on neointimal formation in a porcine coronary model
Tempamine is one of new class of antioxidant agents, the nitroxides, which have shown a wide range of biological effects like suppressing free radical driven reactions to maintain cell functions. The objectives of this study were to evaluate the effect of a biodegradable polymer coated stent loaded with tempamine on in-stent neointimal formation.Stainless steel stents were dip coated in biodegradable elastomeric poly (ester-amide) (co-PEA) or in polymer solution mixed with 50% (wt%) and 100% (wt%) tempamine. One group 100% (wt%) tempamine loaded stents were further dip coated in co-PEA polymer to form a top layer. Stainless steel bare, polymer-only, and different doses tempanine coated stents were implanted into porcine coronary arteries with a stent to artery ratio 1.2:1. Histomorphometric analysis was performed at 5 days and 6 weeks respectively.Histomorphometric analysis showed that the bare, polymer-only and tempamine-coated stents elicited a similar tissue response at 5 days. At 6 weeks, the peri-strut inflammation and neointimal hyperplasia of polymer-only stents were comparable to the bare stents. Compared to the bare stents, 50% tempanine coated stents had a trend to decrease the arterial injury (0.62 +/- 0.41 versus 0.34 +/- 0.18, P = 0.075) and neointimal hyperplasia (1.80 +/- 0.77 versus 1.27 +/- 0.39 mm2, P = 0.085). However, 100% tempanine coated showed significantly increased inflammatory response and neointimal formation.These co-PEA polymer coatings showed a biocompatible performance. Loaded with 50% tempamine had a trend to decrease neointimal hyperplasia. The 100% tempamine for stent-based delivery may have potential cytotoxic effects to arterial wall. Using a co-PEA polymer topcoat could effectively abolish these side effects.
- 1 January 2006
- Published by Taylor & Francis in Acute Cardiac Care
- Vol. 8 (4) , 210-216
Stent?based tempamine delivery on neointimal formation in a porcine coronary model
Tempamine is one of new class of antioxidant agents, the nitroxides, which have shown a wide range of biological effects like suppressing free radical driven reactions to maintain cell functions. The objectives of this study were to evaluate the effect of a biodegradable polymer coated stent loaded with tempamine on in-stent neointimal formation.Stainless steel stents were dip coated in biodegradable elastomeric poly (ester-amide) (co-PEA) or in polymer solution mixed with 50% (wt%) and 100% (wt%) tempamine. One group 100% (wt%) tempamine loaded stents were further dip coated in co-PEA polymer to form a top layer. Stainless steel bare, polymer-only, and different doses tempanine coated stents were implanted into porcine coronary arteries with a stent to artery ratio 1.2:1. Histomorphometric analysis was performed at 5 days and 6 weeks respectively.Histomorphometric analysis showed that the bare, polymer-only and tempamine-coated stents elicited a similar tissue response at 5 days. At 6 weeks, the peri-strut inflammation and neointimal hyperplasia of polymer-only stents were comparable to the bare stents. Compared to the bare stents, 50% tempanine coated stents had a trend to decrease the arterial injury (0.62 +/- 0.41 versus 0.34 +/- 0.18, P = 0.075) and neointimal hyperplasia (1.80 +/- 0.77 versus 1.27 +/- 0.39 mm2, P = 0.085). However, 100% tempanine coated showed significantly increased inflammatory response and neointimal formation.These co-PEA polymer coatings showed a biocompatible performance. Loaded with 50% tempamine had a trend to decrease neointimal hyperplasia. The 100% tempamine for stent-based delivery may have potential cytotoxic effects to arterial wall. Using a co-PEA polymer topcoat could effectively abolish these side effects.
- 14 June 2005
- Published by Taylor & Francis
- p. 457-469
Dexamethasone
- 14 June 2005
- Published by Taylor & Francis
- p. 443-455
The Blue Medical 50% TEMPO coronary stent
- 14 June 2005
- Published by Taylor & Francis
- p. 307-310
Biocompatibility evaluation of biosoluble stent coatings in a porcine coronary stent model
- 14 June 2005
- Published by Taylor & Francis
- p. 307-310
Biocompatibility evaluation of biosoluble stent coatings in a porcine coronary stent model
- 14 June 2005
- Published by Taylor & Francis
- p. 297-306
Long-term biocompatibility evaluation of poly-bis-trifluorethoxyphosphazene (PTFEP)
- 14 June 2005
- Published by Taylor & Francis
- p. 297-306
Long-term biocompatibility evaluation of poly-bis-trifluorethoxyphosphazene (PTFEP)
- 1 April 2003
- Vol. 15 (4) , 191-7
Arterial wall temperature following coronary stent implantation in pigs: the role of post-stent inflammation.
The purpose of this study was to investigate in vivo the arterial wall temperature after coronary stent implantation in pigs. We performed cardiac catheterization in 20 pigs with normal coronary arteries. Arterial wall temperature was studied with a thermography system that uses a 4-thermistor sensor tip. A segment was selected in the proximal right coronary artery. Temperature was mapped in this segment by means of a continuous catheter pullback. A stent was then implanted in the middle of this area, and the temperature scan was repeated. Pigs were randomized in two groups (10 + 10 pigs) for arterial temperature scanning: group A to be re-scanned after 5 days and then sacrificed, and group B to be re-scanned after 8 days and then sacrificed. The temperature of the arterial wall before stent implantation was equal to the adjacent areas. Immediately after stent implantation, the stented area had lower temperature than the adjacent areas (p < 0.001). Five days after implantation, the stented area was significantly warmer than the adjacent areas (p < 0.001); histopathology showed the highest macrophage population at the place of the stent. Eight days after implantation, the temperature differences were reduced to non-significant levels (p = NS) and the macrophage population was significantly lower. Stent implantation results in an immediate temperature decrease at the stented arterial segment, followed by a significant temperature increase around day 5 after stent implantation. These findings can be correlated with the peri-strut inflammation that follows the stent implantation.
- 1 April 2003
- Vol. 15 (4) , 191-7
Arterial wall temperature following coronary stent implantation in pigs: the role of post-stent inflammation.
The purpose of this study was to investigate in vivo the arterial wall temperature after coronary stent implantation in pigs. We performed cardiac catheterization in 20 pigs with normal coronary arteries. Arterial wall temperature was studied with a thermography system that uses a 4-thermistor sensor tip. A segment was selected in the proximal right coronary artery. Temperature was mapped in this segment by means of a continuous catheter pullback. A stent was then implanted in the middle of this area, and the temperature scan was repeated. Pigs were randomized in two groups (10 + 10 pigs) for arterial temperature scanning: group A to be re-scanned after 5 days and then sacrificed, and group B to be re-scanned after 8 days and then sacrificed. The temperature of the arterial wall before stent implantation was equal to the adjacent areas. Immediately after stent implantation, the stented area had lower temperature than the adjacent areas (p < 0.001). Five days after implantation, the stented area was significantly warmer than the adjacent areas (p < 0.001); histopathology showed the highest macrophage population at the place of the stent. Eight days after implantation, the temperature differences were reduced to non-significant levels (p = NS) and the macrophage population was significantly lower. Stent implantation results in an immediate temperature decrease at the stented arterial segment, followed by a significant temperature increase around day 5 after stent implantation. These findings can be correlated with the peri-strut inflammation that follows the stent implantation.
- 1 September 2002
- Vol. 14 (9) , 505-13
Optimization of local methylprednisolone delivery to inhibit inflammatory reaction and neointimal hyperplasia of coated coronary stents.
Polymer coating can optimize the surface characteristics of metallic coronary stents and serve as a vehicle for local drug delivery. Major problems, however, include the lack of biocompatibility of the polymers used and the limited amount of drug that can be loaded onto the stent. Stainless-steel stents were spray-coated or spray-coated combined with a barrier coating using a fluorinated polymethacrylate PFM-P75 impregnated with different methylprednisolone concentrations. When spray-coated with highly concentrated methylprednisolone ( 33%) fluorinated polymethacrylate PFM-P75, the surface became progressively more rough. Adding a barrier coating, however, could decrease these surface irregularities of methylprednisolone-loaded PFM-P75 spray-coated stents. In vitro, most of the methylprednisolone was released in the first 48 hours. A barrier coating could dramatically slow down the drug release from 80% to 13% during the first 48 hours. Histomorphometric analysis showed that the inflammatory response and neointimal hyperplasia of methylprednisolone-loaded stents were lower than in control stents. Neointimal hyperplasia of methylprednisolone-loaded PFM-P75 stents spray-coated with a barrier coating was decreased compared to the non-barrier-coated methylprednisolone-loaded stents. In conclusion, spray coating enables the use of high methylprednisolone concentrations. A barrier coating could significantly slow down the methylprednisolone release. Methylprednisolone-loaded PFM-P75-coated stents could significantly inhibit the inflammatory response and neointimal hyperplasia. The response to methylprednisolone was related to the dose used and the release time of the drug.
- 1 September 2002
- Vol. 14 (9) , 505-13
Optimization of local methylprednisolone delivery to inhibit inflammatory reaction and neointimal hyperplasia of coated coronary stents.
Polymer coating can optimize the surface characteristics of metallic coronary stents and serve as a vehicle for local drug delivery. Major problems, however, include the lack of biocompatibility of the polymers used and the limited amount of drug that can be loaded onto the stent. Stainless-steel stents were spray-coated or spray-coated combined with a barrier coating using a fluorinated polymethacrylate PFM-P75 impregnated with different methylprednisolone concentrations. When spray-coated with highly concentrated methylprednisolone ( 33%) fluorinated polymethacrylate PFM-P75, the surface became progressively more rough. Adding a barrier coating, however, could decrease these surface irregularities of methylprednisolone-loaded PFM-P75 spray-coated stents. In vitro, most of the methylprednisolone was released in the first 48 hours. A barrier coating could dramatically slow down the drug release from 80% to 13% during the first 48 hours. Histomorphometric analysis showed that the inflammatory response and neointimal hyperplasia of methylprednisolone-loaded stents were lower than in control stents. Neointimal hyperplasia of methylprednisolone-loaded PFM-P75 stents spray-coated with a barrier coating was decreased compared to the non-barrier-coated methylprednisolone-loaded stents. In conclusion, spray coating enables the use of high methylprednisolone concentrations. A barrier coating could significantly slow down the methylprednisolone release. Methylprednisolone-loaded PFM-P75-coated stents could significantly inhibit the inflammatory response and neointimal hyperplasia. The response to methylprednisolone was related to the dose used and the release time of the drug.